🇺🇸 FDA
Patent

US 11084856

Interleukin-4 receptor-binding fusion proteins and uses thereof

granted A61KA61K38/00A61K38/1761

Quick answer

US patent 11084856 (Interleukin-4 receptor-binding fusion proteins and uses thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K38/00, A61K38/1761, A61K38/193, A61K38/2026